Faheem Hasnain - 09 Dec 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Reporting relationship: Director
Issuer ticker: KURA
Reported as of: 09 Dec 2025
Net transaction value: -$78,564
SEC form: 4
Accepted by SEC: 10 Dec 2025, 16:05:03 UTC
Prior SEC filing: 02 Oct 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Teresa Bair, Attorney-in-fact for Faheem Hasnain

Key filing fact

Faheem Hasnain filed Form 4 for Kura Oncology, Inc. (KURA) on 10 Dec 2025.

Key facts

This page summarizes Faheem Hasnain's Form 4 filing for Kura Oncology, Inc. (KURA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Dec 2025, 16:05.

Change

Previous filing in this sequence was filed on 02 Oct 2025.
Current net transaction value: -$78,564.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001352620 Primary reporting owner

Hasnain Faheem

Relationship: Director
Address: C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO
Signature: /s/ Teresa Bair, Attorney-in-fact for Faheem Hasnain
Signature date: 10 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KURA transaction

Common Stock

Options Exercise

Transaction value: $31,200
Shares: +10,000
Change %: +42%
Price: $3.12
Shares after: 33,983
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1

KURA transaction

Common Stock

Sale

Transaction value: $109,764
Shares: -10,000
Change %: -29%
Price: $10.98
Shares after: 23,983
Date: 09 Dec 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $10.60 to $11.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.